Melinta Therapeutics, Inc., incorporated on May 16, 2008, develops and commercializes novel antibiotics designed to provide therapeutic solutions. The Company’s lead product is Baxdela, an antibiotic approved by the United States food and drug administration (FDA) for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). The Company also has an extensive pipeline of preclinical and clinical stage products This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market.The Company is primarily comprised of the infectious disease activities related to Minocin IV, Orbactiv, and Vabomere, and other preclinical product candidates. The Company’s marketed product portfolio has Minocin, (minocycline), for injection Orbactiv, (oritavancin) and Vabomere.
|Bank Name||Melinta Therapeutics, Inc.|
|CEO||Dr. Erin M. Duffy Ph.d.|